US EditionPublished • loading... • Updated
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
Summary by ABC FOX Montana
23 Articles
23 Articles
ABC FOX Montana+22 Reposted by 22 other sources
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
Safety & efficacy of iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC) in combination with serplulimab (an anti-PD1 antibody), in treatment-naive patients with Extensive stage Small Cell Lung Cancer (ES-SCLC) will be presented
·Missoula, United States
Read Full ArticleCoverage Details
Total News Sources23
Leaning Left1Leaning Right1Center9Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
C 82%
Factuality
To view factuality data please Upgrade to Premium
